MedPath

Besifloxacin

Generic Name
Besifloxacin
Brand Names
Besivance
Drug Type
Small Molecule
Chemical Formula
C19H21ClFN3O3
CAS Number
141388-76-3
Unique Ingredient Identifier
BFE2NBZ7NX

Overview

Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

Background

Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

Indication

Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*

Associated Conditions

  • Bacterial Conjunctivitis

FDA Approved Products

Besivance
Manufacturer:Bausch & Lomb Incorporated
Route:OPHTHALMIC
Strength:6 mg in 1 mL
Approved: 2022/02/02
NDC:24208-446
BESIVANCE
Manufacturer:A-S Medication Solutions
Route:OPHTHALMIC
Strength:6 mg in 1 mL
Approved: 2022/02/02
NDC:50090-1241
Besivance
Manufacturer:Physicians Total Care, Inc.
Route:OPHTHALMIC
Strength:6 mg in 1 mL
Approved: 2011/07/22
NDC:54868-6282

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath